Envista (NVST) to Release Earnings on Thursday

Envista (NYSE:NVST) is expected to announce its Q4 2025 results after the market closes on Thursday, February 5th. Analysts expect the company to announce earnings of $0.32 per share and revenue of $680.2550 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 5, 2026 at 5:00 PM ET.

Envista (NYSE:NVST) last released its quarterly earnings results on Wednesday, October 29th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.27 by $0.05. Envista had a return on equity of 5.90% and a net margin of 0.58%.The company had revenue of $669.90 million during the quarter, compared to analyst estimates of $639.49 million. During the same quarter last year, the business posted $0.12 earnings per share. The firm’s revenue was up 11.5% on a year-over-year basis. On average, analysts expect Envista to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Envista Trading Down 0.1%

Shares of NVST stock opened at $24.09 on Thursday. The company has a market cap of $3.96 billion, a PE ratio of 267.64, a price-to-earnings-growth ratio of 1.07 and a beta of 0.99. Envista has a 1 year low of $14.22 and a 1 year high of $25.41. The stock’s 50 day simple moving average is $22.25 and its two-hundred day simple moving average is $21.01. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.37 and a quick ratio of 2.02.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on NVST. Mizuho set a $24.00 price target on Envista and gave the company a “neutral” rating in a report on Tuesday, January 20th. Stifel Nicolaus set a $25.00 price objective on shares of Envista in a research report on Thursday, October 30th. Weiss Ratings reissued a “sell (d)” rating on shares of Envista in a research note on Monday, December 29th. Wall Street Zen upgraded shares of Envista from a “buy” rating to a “strong-buy” rating in a report on Monday. Finally, Robert W. Baird set a $27.00 price target on shares of Envista in a report on Friday, October 31st. Five analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $22.17.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd lifted its holdings in Envista by 16,711.1% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 1,513 shares of the company’s stock valued at $31,000 after buying an additional 1,504 shares in the last quarter. PharVision Advisers LLC purchased a new position in shares of Envista during the third quarter worth approximately $307,000. XTX Topco Ltd raised its stake in shares of Envista by 90.4% during the third quarter. XTX Topco Ltd now owns 81,347 shares of the company’s stock valued at $1,657,000 after acquiring an additional 38,628 shares in the last quarter. Virtus Advisers LLC purchased a new stake in shares of Envista in the third quarter valued at approximately $205,000. Finally, Verition Fund Management LLC boosted its holdings in shares of Envista by 15.9% in the third quarter. Verition Fund Management LLC now owns 164,084 shares of the company’s stock valued at $3,342,000 after purchasing an additional 22,566 shares during the period.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.